Literature DB >> 26261525

JMJD5 is a potential oncogene for colon carcinogenesis.

Ru Zhang1, Qingjun Huang1, Yinpeng Li1, Yang Song1, Yingxue Li1.   

Abstract

OBJECTIVE: To observe the effects of Jumonji C domain-containing (JMJD) 5 depletion on colon cancer (CC).
METHODS: A short-hairpin RNA targeting JMJD5 was transfected into a lentivirus to make Lv-shJMJD5 for infection into the Caco-2 human cell. Besides, a negative control shRNA was constructed. The mRNA and protein levels of JMJD5 were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting, respectively. Cell proliferation, migration, and invasion were assessed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), soft agar colony assay and transwell assay, respectively. In addition, immunohistochemical (IHC) staining was performed to investigate the expression of JMJD5 in adjacent normal tissues and tumor tissues from patients with CC.
RESULTS: Compared with control group, mRNA and protein levels of JMJD5 was significantly reduced after infection with Lv-shJMJD5 (P<0.05), and Caco-2 cell proliferation, migration, and invasion were all obviously inhibited (P<0.05). The results of IHC showed that JMJD5 was significantly up-regulated compared with normal tissues (P<0.01). Additionally, follow-up data demonstrated that the survival rate of patients with high expression of JMJD5 was obviously lower than that with low expression (P<0.01).
CONCLUSIONS: JMJD5 depletion could significantly inhibit human CC cell proliferation, migration, and invasion, implying that JMJD5 might be a potential oncogene.

Entities:  

Keywords:  Colon cancer; JMJD5; Lv-shJMJD5; invasion; migration; proliferation

Mesh:

Substances:

Year:  2015        PMID: 26261525      PMCID: PMC4525859     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

Review 1.  Interplay between chromatin modifications and paused RNA polymerase II in dynamic transition between stalled and activated genes.

Authors:  Shuang Liu; Yongguang Tao
Journal:  Biol Rev Camb Philos Soc       Date:  2012-07-06

Review 2.  Functions, aberrations, and advances for chromatin modulation in cancer.

Authors:  Mariarosaria Conte; Lucia Altucci
Journal:  Cancer Treat Res       Date:  2014

3.  Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR.

Authors:  Roberto Benelli; Roberta Venè; Simona Minghelli; Sebastiano Carlone; Beatrice Gatteschi; Nicoletta Ferrari
Journal:  Cancer Lett       Date:  2012-09-23       Impact factor: 8.679

4.  Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases.

Authors:  Johnathan R Whetstine; Amanda Nottke; Fei Lan; Maite Huarte; Sarit Smolikov; Zhongzhou Chen; Eric Spooner; En Li; Gongyi Zhang; Monica Colaiacovo; Yang Shi
Journal:  Cell       Date:  2006-04-06       Impact factor: 41.582

Review 5.  Genetic and epigenetic alterations in colon cancer.

Authors:  William M Grady; Sanford D Markowitz
Journal:  Annu Rev Genomics Hum Genet       Date:  2002-04-15       Impact factor: 8.929

6.  JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism.

Authors:  Hung-Jung Wang; Ya-Ju Hsieh; Wen-Chi Cheng; Chun-Pu Lin; Yu-shan Lin; So-Fang Yang; Chung-Ching Chen; Yoshihiro Izumiya; Jau-Song Yu; Hsing-Jien Kung; Wen-Ching Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

7.  Crystal structure and functional analysis of JMJD5 indicate an alternate specificity and function.

Authors:  Paul A Del Rizzo; Swathi Krishnan; Raymond C Trievel
Journal:  Mol Cell Biol       Date:  2012-07-30       Impact factor: 4.272

8.  JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation.

Authors:  Feng Wang; Lin He; Peiwei Huangyang; Jing Liang; Wenzhe Si; Ruorong Yan; Xiao Han; Shumeng Liu; Bin Gui; Wanjin Li; Di Miao; Chao Jing; Zhihua Liu; Fei Pei; Luyang Sun; Yongfeng Shang
Journal:  PLoS Biol       Date:  2014-03-25       Impact factor: 8.029

Review 9.  Status of large-scale analysis of post-translational modifications by mass spectrometry.

Authors:  Jesper V Olsen; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2013-11-01       Impact factor: 5.911

Review 10.  PKM2: the thread linking energy metabolism reprogramming with epigenetics in cancer.

Authors:  Ling Chen; Ying Shi; Shuang Liu; Ya Cao; Xiang Wang; Yongguang Tao
Journal:  Int J Mol Sci       Date:  2014-06-26       Impact factor: 5.923

View more
  11 in total

Review 1.  The small members of the JMJD protein family: Enzymatic jewels or jinxes?

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680

2.  Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Authors:  Noël J-M Raynal; Elodie M Da Costa; Justin T Lee; Vazganush Gharibyan; Saira Ahmed; Hanghang Zhang; Takahiro Sato; Gabriel G Malouf; Jean-Pierre J Issa
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

3.  Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx.

Authors:  Takahisa Kouwaki; Toru Okamoto; Ayano Ito; Yukari Sugiyama; Kazuo Yamashita; Tatsuya Suzuki; Shinji Kusakabe; Junki Hirano; Takasuke Fukuhara; Atsuya Yamashita; Kazunobu Saito; Daisuke Okuzaki; Koichi Watashi; Masaya Sugiyama; Sachiyo Yoshio; Daron M Standley; Tatsuya Kanto; Masashi Mizokami; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

4.  Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability.

Authors:  Junyu Wu; Zhimin He; Da-Liang Wang; Fang-Lin Sun
Journal:  Cell Cycle       Date:  2016-10-07       Impact factor: 4.534

5.  JMJD5 is a human arginyl C-3 hydroxylase.

Authors:  Sarah E Wilkins; Md Saiful Islam; Joan M Gannon; Suzana Markolovic; Richard J Hopkinson; Wei Ge; Christopher J Schofield; Rasheduzzaman Chowdhury
Journal:  Nat Commun       Date:  2018-03-21       Impact factor: 14.919

6.  KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.

Authors:  Hung-Jung Wang; Mamata Pochampalli; Ling-Yu Wang; June X Zou; Pei-Shan Li; Sheng-Chieh Hsu; Bi-Juan Wang; Shih-Han Huang; Ping Yang; Joy C Yang; Cheng-Ying Chu; Chia-Ling Hsieh; Shian-Ying Sung; Chien-Feng Li; Clifford G Tepper; David K Ann; Allen C Gao; Christopher P Evans; Yoshihiro Izumiya; Chi-Pin Chuu; Wen-Ching Wang; Hong-Wu Chen; Hsing-Jien Kung
Journal:  Oncogene       Date:  2018-08-02       Impact factor: 9.867

Review 7.  Human 2-oxoglutarate-dependent oxygenases: nutrient sensors, stress responders, and disease mediators.

Authors:  Sally C Fletcher; Mathew L Coleman
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

8.  WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11.

Authors:  Shuqin Xing; Yafei Wang; Kaiwen Hu; Fen Wang; Tao Sun; Quanwang Li
Journal:  Biosci Rep       Date:  2020-09-30       Impact factor: 3.840

9.  Jumonji domain containing 5 is a potential prognostic indicator in non-small cell lung cancer patients who received platinum-based chemotherapy.

Authors:  Xueping Xiang; Xiaojing Ma; Mao Fang; Like Zhong; Hui Liu; Hong Liu; Yinghui Tong
Journal:  Transl Cancer Res       Date:  2019-11       Impact factor: 1.241

10.  Elevated Expression of JMJD5 Protein Due to Decreased miR-3656 Levels Contributes to Cancer Stem Cell-Like Phenotypes under Overexpression of Cancer Upregulated Gene 2.

Authors:  Natpaphan Yawut; Il-Rae Cho; Phatcharaporn Budluang; Sirichat Kaowinn; Chutima Kaewpiboon; Byeoleun Jeon; Sang-Woo Kim; Ho Young Kang; Min-Kyung Kang; Sang Seok Koh; Young-Hwa Chung
Journal:  Biomolecules       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.